Fezile Özdemir1, Yağmur Kır2, Kenan Can Tok1, Bora Baskak2, Halit Sinan Süzen3. 1. Ankara University Institute of Forensic Sciences, Department of Forensic Toxicology, Ankara, Turkey. 2. Ankara University Faculty of Medicine, Department of Psychiatry, Ankara, Turkey. 3. Ankara University Faculty of Pharmacy, Department of Pharmacology and Toxicology, Ankara, Turkey.
Abstract
OBJECTIVES: Gene variation in the cholinergic muscarinic receptor 1 (CHRM1) has potential to become a candidate biomarker in the development of several disorders as well as drug response. In this study, a novel polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was developed to determine the C to A single nucleotide polymorphism at position 267 in the CHRM1 gene. MATERIALS AND METHODS: A new reverse primer and a mismatched forward primer were designed to obtain 125 bp PCR products. The PCR products were then digested with the Hae III restriction enzyme to detect the rs2067477 polymorphism that comprises a C to A base change. The novel assay developed was tested in 51 Turkish schizophrenia patients. RESULTS: The genotyping assay was successfully performed in patients with schizophrenia in order to confirm the accuracy and validity of this method. The frequency of CC, CA, and AA genotypes was 72.5%, 25.5%, and 2%, respectively. On the basis of these findings, the allele frequency of C was 0.85 and the allele frequency of A was 0.15. CONCLUSION: This genotyping assay is practical for screening the CHRM1 C267A polymorphism in pharmacogenetic studies. The present polymorphism may be used as a candidate biomarker to determine genetic susceptibility to related diseases and may contribute to the implementation of individualized drug therapy for M1-related diseases.
OBJECTIVES: Gene variation in the cholinergic muscarinic receptor 1 (CHRM1) has potential to become a candidate biomarker in the development of several disorders as well as drug response. In this study, a novel polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was developed to determine the C to A single nucleotide polymorphism at position 267 in the CHRM1 gene. MATERIALS AND METHODS: A new reverse primer and a mismatched forward primer were designed to obtain 125 bp PCR products. The PCR products were then digested with the Hae III restriction enzyme to detect the rs2067477 polymorphism that comprises a C to A base change. The novel assay developed was tested in 51 Turkish schizophrenia patients. RESULTS: The genotyping assay was successfully performed in patients with schizophrenia in order to confirm the accuracy and validity of this method. The frequency of CC, CA, and AA genotypes was 72.5%, 25.5%, and 2%, respectively. On the basis of these findings, the allele frequency of C was 0.85 and the allele frequency of A was 0.15. CONCLUSION: This genotyping assay is practical for screening the CHRM1 C267A polymorphism in pharmacogenetic studies. The present polymorphism may be used as a candidate biomarker to determine genetic susceptibility to related diseases and may contribute to the implementation of individualized drug therapy for M1-related diseases.
Authors: Vanessa L Cropley; Elizabeth Scarr; Alex Fornito; Paul Klauser; Chad A Bousman; Rodney Scott; Murray J Cairns; Paul A Tooney; Christos Pantelis; Brian Dean Journal: Psychiatry Res Date: 2015-09-10 Impact factor: 3.222
Authors: Elizabeth Scarr; Suresh Sundram; Azita Deljo; Tiffany Francis Cowie; Andrew Stuart Gibbons; Susan Juzva; Andrew Mackinnon; Stephen J Wood; Renee Testa; Christos Pantelis; Brian Dean Journal: Schizophr Res Date: 2012-03-04 Impact factor: 4.939
Authors: Sean P Carruthers; Vanessa Cropley; Chad Bousman; Ian P Everall; Erica Neill; Christos Pantelis; Philip J Sumner; Eric J Tan; Kiymet Bozaoglu; Elizabeth H X Thomas; Tamsyn E Van Rheenen; Caroline T Gurvich; Susan L Rossell Journal: Psychiatry Res Date: 2019-01-11 Impact factor: 3.222